A detailed history of Rice Hall James & Associates, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Rice Hall James & Associates, LLC holds 730,190 shares of RVNC stock, worth $1.88 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
730,190
Previous 712,072 2.54%
Holding current value
$1.88 Million
Previous $1.83 Million 2.51%
% of portfolio
0.11%
Previous 0.12%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$2.57 - $2.57 $46,563 - $46,563
18,118 Added 2.54%
730,190 $1.88 Million
Q2 2024

Aug 07, 2024

SELL
$2.34 - $4.73 $79,716 - $161,136
-34,067 Reduced 4.57%
712,072 $1.83 Million
Q1 2024

Apr 23, 2024

SELL
$4.65 - $9.31 $55,376 - $110,872
-11,909 Reduced 1.57%
746,139 $3.67 Million
Q4 2023

Feb 08, 2024

BUY
$5.81 - $11.2 $430,584 - $830,043
74,111 Added 10.84%
758,048 $6.66 Million
Q3 2023

Nov 02, 2023

BUY
$11.47 - $25.07 $1.51 Million - $3.3 Million
131,442 Added 23.79%
683,937 $7.84 Million
Q2 2023

Jul 24, 2023

SELL
$24.7 - $37.61 $6.34 Million - $9.65 Million
-256,681 Reduced 31.72%
552,495 $14 Million
Q1 2023

May 11, 2023

SELL
$18.36 - $35.27 $1.22 Million - $2.34 Million
-66,320 Reduced 7.58%
809,176 $26.1 Million
Q4 2022

Jan 27, 2023

SELL
$18.32 - $30.66 $389,446 - $651,770
-21,258 Reduced 2.37%
875,496 $0
Q3 2022

Nov 01, 2022

SELL
$14.33 - $28.47 $2.7 Million - $5.37 Million
-188,586 Reduced 17.38%
896,754 $24.2 Million
Q2 2022

Aug 08, 2022

SELL
$11.52 - $20.4 $310,867 - $550,494
-26,985 Reduced 2.43%
1,085,340 $15 Million
Q1 2022

May 05, 2022

SELL
$12.36 - $20.31 $20,023 - $32,902
-1,620 Reduced 0.15%
1,112,325 $21.7 Million
Q4 2021

Feb 14, 2022

BUY
$12.46 - $27.87 $2.42 Million - $5.41 Million
194,185 Added 21.11%
1,113,945 $18.2 Million
Q3 2021

Nov 09, 2021

SELL
$25.78 - $33.21 $158,031 - $203,577
-6,130 Reduced 0.66%
919,760 $25.6 Million
Q2 2021

Jul 29, 2021

SELL
$26.8 - $31.84 $4.84 Million - $5.75 Million
-180,657 Reduced 16.33%
925,890 $27.4 Million
Q1 2021

May 14, 2021

SELL
$24.03 - $29.97 $350,958 - $437,711
-14,605 Reduced 1.3%
1,106,547 $30.9 Million
Q4 2020

Feb 16, 2021

SELL
$23.41 - $28.34 $207,506 - $251,205
-8,864 Reduced 0.78%
1,121,152 $31.8 Million
Q3 2020

Nov 16, 2020

BUY
$23.23 - $34.3 $2.25 Million - $3.32 Million
96,737 Added 9.36%
1,130,016 $28.4 Million
Q2 2020

Aug 14, 2020

BUY
$12.6 - $26.55 $37,774 - $79,596
2,998 Added 0.29%
1,033,279 $25.2 Million
Q1 2020

May 15, 2020

SELL
$12.46 - $27.81 $446,653 - $996,905
-35,847 Reduced 3.36%
1,030,281 $15.2 Million
Q4 2019

Jan 29, 2020

SELL
$11.66 - $20.15 $146,554 - $253,265
-12,569 Reduced 1.17%
1,066,128 $17.3 Million
Q3 2019

Oct 30, 2019

BUY
$10.22 - $14.5 $2 Million - $2.84 Million
195,928 Added 22.19%
1,078,697 $14 Million
Q2 2019

Aug 01, 2019

BUY
$10.67 - $15.49 $8.17 Million - $11.9 Million
765,701 Added 654.07%
882,769 $11.5 Million
Q1 2019

May 01, 2019

BUY
$15.4 - $20.39 $1.29 Million - $1.71 Million
83,875 Added 252.69%
117,068 $1.85 Million
Q4 2018

Feb 14, 2019

BUY
$18.06 - $24.96 $159,307 - $220,172
8,821 Added 36.19%
33,193 $668,000
Q3 2018

Oct 25, 2018

BUY
$23.55 - $30.1 $573,960 - $733,597
24,372 New
24,372 $606,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Rice Hall James & Associates, LLC Portfolio

Follow Rice Hall James & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rice Hall James & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rice Hall James & Associates, LLC with notifications on news.